214 related articles for article (PubMed ID: 28499700)
1. Imatinib mesylate- and dasatinib-induced eosinophilia in a patient with chronic myelocytic leukemia.
McGrath K; Stein B; Kalhagen L; Leighton L
Ann Allergy Asthma Immunol; 2017 Jul; 119(1):85-86. PubMed ID: 28499700
[No Abstract] [Full Text] [Related]
2. Successful Use of Dasatinib After Liver Transplantation for Imatinib-Induced Fulminant Liver Failure in Chronic Myeloid Leukemia.
Harding DJ; MacQuillan G; Howman R; de Boer B; Adams L; Mitchell A; Jeffrey G
J Clin Oncol; 2016 Apr; 34(11):e97-8. PubMed ID: 25267743
[No Abstract] [Full Text] [Related]
3. Should vascular effects of newer treatments be addressed more completely?
Yang EH; Watson KE; Herrmann J
Future Oncol; 2015; 11(14):1995-8. PubMed ID: 26198824
[No Abstract] [Full Text] [Related]
4. Drug reaction with eosinophilia and systemic symptoms (DRESS) induced by imatinib in chronic myeloid leukemia.
Vatel O; Aumont C; Mathy V; Petit M; Feriel J; Sloma I; Bennaceur-Griscelli A; Turhan AG
Leuk Lymphoma; 2017 Feb; 58(2):473-474. PubMed ID: 27389710
[No Abstract] [Full Text] [Related]
5. Dasatinib induces severe hemorrhagic colitis in a patient with accelerated phase of chronic myelogenous leukemia.
Yim E; Choi YG; Nam YJ; Lee J; Kim JA
Korean J Intern Med; 2018 Mar; 33(2):446-448. PubMed ID: 26961484
[No Abstract] [Full Text] [Related]
6. Cystic acne due to imatinib therapy for chronic myelocytic leukemia.
Hwang A; Iskandar A; Del Rosario M; Dasanu CA
J Oncol Pharm Pract; 2019 Jun; 25(4):972-974. PubMed ID: 29498323
[TBL] [Abstract][Full Text] [Related]
7. Insights into dasatinib use and outcomes in real-world patients with chronic myeloid leukemia.
Adattini JA; Gross AS; Doo NW; McLachlan AJ
Haematologica; 2023 Aug; 108(8):2224-2228. PubMed ID: 36655426
[No Abstract] [Full Text] [Related]
8. Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy.
Racil Z; Koritakova E; Sacha T; Klamova H; Belohlavkova P; Faber E; Rea D; Malaskova L; Prochazkova J; Zackova D; Voglova J; Wącław J; Cetkovsky P; Zak P; Mayer J
Am J Hematol; 2018 Oct; 93(10):E342-E345. PubMed ID: 30054949
[No Abstract] [Full Text] [Related]
9. Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.
Khoury HJ; Goldberg SL; Mauro MJ; Stone RM; Deininger MW; Bradley-Garelik MB; Mohamed H; Guilhot F
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):341-349.e1. PubMed ID: 27133948
[TBL] [Abstract][Full Text] [Related]
10. Imatinib-induced psoriasiform eruption in a patient with chronic myeloid leukemia.
Shi CR; Nambudiri VE
Am J Hematol; 2018 Mar; 93(3):467-468. PubMed ID: 28836284
[No Abstract] [Full Text] [Related]
11. Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series.
Rafei H; Jabbour EJ; Kantarjian H; Sinicrope KD; Kamiya-Matsuoka C; Mehta RS; Daver NG; Kadia TM; Naqvi K; Cortes J; Konopleva M
Leuk Lymphoma; 2019 Dec; 60(13):3292-3295. PubMed ID: 31246142
[No Abstract] [Full Text] [Related]
12. Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.
Gambacorti-Passerini C; Piazza R
JAMA Oncol; 2015 May; 1(2):143-4. PubMed ID: 26181011
[No Abstract] [Full Text] [Related]
13. Horizontal melanonychia.
Salman A; Eser A; Kaygusuz Atagunduz I; Ergun T
Actas Dermosifiliogr; 2017 Jun; 108(5):469-470. PubMed ID: 27543192
[No Abstract] [Full Text] [Related]
14. Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation.
Numata A; Kajiyama R; Itabashi M; Ishii Y; Yamamoto W; Motohashi K; Matsumoto K; Hagihara M; Ishigatsubo Y; Fujisawa S
Leuk Lymphoma; 2016; 57(1):201-2. PubMed ID: 25860242
[No Abstract] [Full Text] [Related]
15. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
Schiffer CA; Cortes JE; Hochhaus A; Saglio G; le Coutre P; Porkka K; Mustjoki S; Mohamed H; Shah NP
Cancer; 2016 May; 122(9):1398-407. PubMed ID: 26998677
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate-induced pseudoporphyria in a patient with chronic myeloid leukemia.
Batrani M; Salhotra M; Kubba A; Agrawal M
Indian J Dermatol Venereol Leprol; 2016; 82(6):727-729. PubMed ID: 27716725
[No Abstract] [Full Text] [Related]
17. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib-induced loss of eyebrows.
Naithani R
Br J Haematol; 2017 Nov; 179(3):362. PubMed ID: 28737227
[No Abstract] [Full Text] [Related]
19. Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors.
Weatherald J; Bondeelle L; Chaumais MC; Guignabert C; Savale L; Jaïs X; Sitbon O; Rousselot P; Humbert M; Bergeron A; Montani D
Eur Respir J; 2020 Oct; 56(4):. PubMed ID: 32527740
[TBL] [Abstract][Full Text] [Related]
20. Large granular lymphocytosis induced by dasatinib.
Fernandes F; Ramalho R; Barreira R; Silveira M; Bain BJ
Am J Hematol; 2021 Mar; 96(3):395-396. PubMed ID: 32757492
[No Abstract] [Full Text] [Related]
[Next] [New Search]
